China
Africa
Explore chapters and articles related to this topic
Prescribing for a first episode of affective psychosis
Published in Kathy J Aitchison, Karena Meehan, Robin M Murray, First Episode Psychosis, 2021
Kathy J Aitchison, Karena Meehan, Robin M Murray
It is important that patients are followed up by healthcare professionals with a high level of commitment. One possibility is in the context of an early psychosis unit, where available. An alternative setting which, in fact, most closely approximates the conditions of the early efficacy studies is the specialized lithium or mood disorders clinic.
Heterocyclic Drugs from Plants
Published in Rohit Dutt, Anil K. Sharma, Raj K. Keservani, Vandana Garg, Promising Drug Molecules of Natural Origin, 2020
Debasish Bandyopadhyay, Valeria Garcia, Felipe Gonzalez
Psychotic disorders are varying illnesses which affect the mind and cause mental disorders. These disorders cause abnormal thinking and perceptions. Psychosis is a mental disorder of feeling disconnected from reality (Early Psychosis and Psychosis, 2018). They make it hard to know what’s real and what isn’t. While the experience for everyone is different, many people say that psychosis is frightening and confusing. In general, “psychotic disorders” indicate schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder, shared psychotic disorder, etc.
Mapping research at the intersection of design and mental health
Published in Ann Petermans, Rebecca Cain, Design for Wellbeing, 2019
The concept of collaboration and ‘working with’, is increasingly evident within UK health services. The NHS ‘Five Year Forward View’ refers to new relationships with patients and communities (NHS England, 2016), and an NHS independent taskforce report (February 2016) highlights the specific need to re-energise and improve mental health care across the NHS through innovative approaches in order to meet increased demand and improve outcomes. In this respect, Larkin et al. (2015) consider inpatient mental health services in the UK to be unsatisfactory for both service-users and staff, reporting on three qualitative research studies concerned with stakeholder experiences of hospitalisation during early psychosis, as a starting point for translation into service improvements developed in collaboration with service-users, carers, community, inpatient staff and management. The paper considers an adapted form of experience-based co-design (EBCD), a participatory action-research method for collaboratively improving health care services. The use of EBCD is still relatively novel in mental health settings; Goodrich and Stanley (2014) include a successful case study of an initiative at Oxleas Foundation Trust, while Larkin et al. (2015) discuss adaptations to the methodology and the implications of using EBCD with vulnerable populations in complex services. Carr et al. (2011) investigate connections between evidence-based and experience-based methods in the redesign of services.
Impact of early use of long-acting injectable antipsychotics on functional outcome in first episode psychosis: a 3-year longitudinal study
Published in International Journal of Psychiatry in Clinical Practice, 2023
Amal Abdel-Baki, Émile Poulin, Sofia Medrano, Paula Pires de Oliveira Padilha, Emmanuel Stip, Stéphane Potvin
A prospective longitudinal naturalistic 3-year study took place in two urban early intervention services (EIS) in the Université de Montreal’s network (Quebec, Canada) (Nicole et al., 2007). Both programs offer services to all FEP patients in their respectively defined catchment areas. The EIS were Programme Premier Épisode Psychotique (PEP) of the Institut Universitaire en Santé Mentale de Montréal, covering a population of 340,000 inhabitants in the eastern part of the city, and Clinique Jeunes Adultes Psychotiques (JAP) of the Centre Hospitalier de l'Université de Montréal (CHUM), located in the city centre and covering a catchment area of 225,000 inhabitants. The 5-year programs provide specialised treatment based on early psychosis intervention guidelines, including an array of psychosocial treatments, case management and pharmacological treatment (Group, 2016).
Anhedonia in young people with first episode psychosis: a longitudinal study
Published in Nordic Journal of Psychiatry, 2020
Lorenzo Pelizza, Sara Garlassi, Silvia Azzali, Federica Paterlini, Ilaria Scazza, Luigi Rocco Chiri, Michele Poletti, Simona Pupo, Andrea Raballo
This conceptualization in schizophrenia has been recently questioned by modern laboratory-based studies on hedonic response to pleasant stimuli [6]. Specifically, while the psychometric evaluation of noncurrent hedonic experiences (based on retrospective self-reported questionnaires) showed that individuals with schizophrenia had lower levels of pleasure in comparison with healthy subjects [1,7], recent meta-analyses on current pleasant feelings in laboratory-based research reported comparable valence and arousal in relation to pleasant stimuli between the two groups [8–10]. This ‘emotional paradox’ of noncurrent and current pleasure experience [11] has confused what anhedonia reflects in schizophrenia [6,12]. Therefore, studies on young individuals with early psychosis (such as patients with First Episode Psychosis [FEP]) could offer salient information on when and how this emotional impairment arises [13].
Pharmacological strategies for the management of comorbid depression and schizophrenia
Published in Expert Opinion on Pharmacotherapy, 2020
Numerous studies, including recent genetic data, show that an immune process and inflammation play a role in at least a subgroup of patients with schizophrenia. Perhaps the most convincing evidence for an involvement of inflammation in schizophrenia is provided by the finding that anti-inflammatory medication is useful in schizophrenia [40]. Some agents with anti-inflammatory properties showed efficacy. Recently, an update regarding the efficacy of anti-inflammatory agents for schizophrenia symptoms tested in randomized controlled trials was published. Most anti-inflammatory components have many functions, and their anti-inflammatory actions are just one function and often not the most important one. Augmentation of antipsychotic medication with aspirin, estrogens, minocycline, and N-acetylcysteine improved symptom severity in patients with schizophrenia. The greater beneficial results were observed in early-psychosis studies. However, no studies have used depression as a primary outcome [41]. It is possible that depression (as a core dimension of psychosis) explains some of the commonality in biological findings across mood disorders and schizophrenia and also provides potential etiological pathways and therapeutic targets. We might suggest that depression drives forward further symptom dimensions through a stress-inflammation-structural brain change pathway [3].